Multiple intracrine hormonal targets in the prostate: Opportunities and challenges

BJU International

Volumn 100, Issue SUPPL. 2, 2007, Pages 48-51

  Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; FLUTAMIDE; GONADORELIN AGONIST; NILUTAMIDE; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; DRUG TARGETING; HORMONAL THERAPY; HORMONE ACTION; HUMAN; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 34250862142     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06955.x     Document Type: Review

References (29)

1. Arnst C. Developments to watch. Why did prostate cancer death rates fall? Business Week 2003, 13 October, 92
2. Anonymous. Stat bite: trends in cancer mortality by primary cancer site, 1992-2001. J Natl Cancer Inst 2004 96 : 987
3. Lichtenberg F. Measuring the health impacts of medical innovation and expenditure. Health Services Research Seminar Series 2002-3. University of Minnesota, Minneapolis, MN, USA, 2002. Available at: http://www.hsr.umn.edu/ events/info/02-03_seminars.htm#Lichtenberg. Accessed April 2007
4. Labrie F, Candas B, Cusan L et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996 47 : 212 7
5. Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 2002 60 : 115 9
6. Akaza H, Hinotsu S, Usami M et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol 2006 176 : S47 9
7. Homma Y, Akaza H, Okada K et al. Prostate Cancer Study Group. Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer. Int J Urol 2004 11 : 218 24
8. Egawa M, Misaki T, Imao T et al. Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. Int J Urol 2004 11 : 304 9
9. Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. Int J Urol 2006 13 : 1494 500
10. Burgus R, Butcher M, Ling N et al. [Molecular structure of the hypothalamic factor (LRF) of ovine origin monitoring the secretion of pituitary gonadotropic hormone of luteinization (LH).] C R Acad Sci Hebd Seances Acad Sci D 1971 273 : 1611 3
11. Matsuo H, Baba Y, Nair RM, Arimura A, Schally AV. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971 43 : 1334 9
12. Labrie F, Bélanger A, Cusan L et al. Antifertility effects of LHRH agonists in the male. J Androl 1980 1 : 209 28
13. Faure N, Labrie F, Lemay A et al. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men. Fertil Steril 1982 37 : 416 24
14. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997 337 : 295 300
15. Pilepich MV, Caplan R, Byhardt RW et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997 15 : 1013 21
16. Labrie F, Candas B, Dupont A et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999 38 : 83 91
17. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999 341 : 1781 8
18. Granfors T, Modig H, Damber JE, Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998 159 : 2030 4
19. Hanks G, Lu J, Machtay M et al. RTOG protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 2000 19 (Suppl Abstract 1284
20. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004 292 : 821 7
21. Peto R, Dalesio O. Breast and prostate cancer: 10-year survival gains in the hormonal adjuvant treatment trials. EJC Supplements 2003 1 : S101 (abstract 328)
22. Labrie F, Dupont A, Bélanger A. Complete androgen blockade for the treatment of prostate cancer. In de Vita VT, Hellman S, Rosenberg SA. Important Advances in Oncology. Philadelphia : Lippincott, 1985 : 193 217
23. Labrie F, Bélanger A, Luu-The V et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005 26 : 361 79
24. Labrie F, Dupont A, Bélanger A et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982 5 : 267 75
25. Caubet JF, Tosteson TD, Dong EW et al. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 1997 49 : 71 8
26. Denis LJ, Keuppens F, Smith PH et al. Maximal androgen blockade: final analysis of EORTC phase III trial 30853. Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol 1998 33 : 144 51
27. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 1999 2 : 4 8
28. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 2000 355 : 1491 8
29. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989 321 : 419 24